/
Executive Leadership
Hans Bishop
President, Founder and Board Co-Chair
President, Founder and Board Co-Chair
"Building a company with extraordinary ambition requires extraordinary people. It will also require building an innovation culture that brings out the best in people from very diverse backgrounds. We aim to amplify the best attributes of academia and companies with the goal to accelerate problem solving. I’m excited to be joining a team with such an inspiring mission and the internal ambition of building a company where all of us can say that we are doing our very best work."
Hans Bishop is the President, Founder, and Board Co-Chair of Altos Labs.
Hans served previously as the CEO of GRAIL, which was acquired by Illumina. From 2013 to 2018, he served as President and CEO at Juno Therapeutics, a company that he co-founded and that was acquired by Celgene. Prior to Juno, Hans served as an Executive in Residence at Warburg Pincus. Earlier in his career, he was the Executive Vice President and Chief Operating Officer for Dendreon. Hans also previously served as President of Specialty Medicine at Bayer Healthcare and Senior Vice President of Global Commercial Operations at Chiron Corporation. He currently serves as the Chairman of Sana Biotechnology’s Board of Directors and as a Director on the Board of Lyell Immunopharma.
Hans served previously as the CEO of GRAIL, which was acquired by Illumina. From 2013 to 2018, he served as President and CEO at Juno Therapeutics, a company that he co-founded and that was acquired by Celgene. Prior to Juno, Hans served as an Executive in Residence at Warburg Pincus. Earlier in his career, he was the Executive Vice President and Chief Operating Officer for Dendreon. Hans also previously served as President of Specialty Medicine at Bayer Healthcare and Senior Vice President of Global Commercial Operations at Chiron Corporation. He currently serves as the Chairman of Sana Biotechnology’s Board of Directors and as a Director on the Board of Lyell Immunopharma.